December 3, 2025
The video discusses how clinicians decide whether to treat patients with EGFR-mutated non-small cell lung cancer (NSCLC) using monotherapy (e.g., osimertinib alone) versus combination therapy (such as osimertinib with chemotherapy or other targeted agents). It highlights the latest clinical data showing that combination approaches can improve outcomes like progression-free and overall survival in some patients, but also come with increased toxicity. The focus is on tailoring treatment decisions based on individual patient characteristics, disease burden, mutation profile, and balancing efficacy with side effects to optimize personalized care.
Related Posts
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC
